What is William Blair's Estimate for Harrow Q2 Earnings?

Harrow, Inc. (NASDAQ:HROW - Free Report) - William Blair issued their Q2 2025 EPS estimates for shares of Harrow in a report released on Monday, July 14th. William Blair analyst L. Hanbury-Brown forecasts that the company will earn ($0.03) per share for the quarter. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's FY2025 earnings at $0.06 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. The company had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million.

Other research analysts also recently issued research reports about the stock. HC Wainwright increased their price objective on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. BTIG Research assumed coverage on shares of Harrow in a report on Thursday, June 12th. They issued a "buy" rating and a $62.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Harrow in a report on Friday, July 11th. They issued an "overweight" rating and a $76.00 price target for the company. Finally, B. Riley lowered their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Harrow presently has an average rating of "Buy" and an average target price of $63.83.

Harrow Price Performance

Shares of HROW traded up $0.36 during midday trading on Wednesday, hitting $36.50. 152,457 shares of the company traded hands, compared to its average volume of 498,387. The firm has a 50 day moving average of $29.90 and a 200-day moving average of $28.86. Harrow has a 52 week low of $20.85 and a 52 week high of $59.23. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -64.94 and a beta of 0.41. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in Harrow in the fourth quarter worth about $25,000. Quarry LP bought a new stake in Harrow in the first quarter worth about $32,000. Tower Research Capital LLC TRC lifted its stake in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Harrow in the fourth quarter worth about $78,000. Finally, State of Wyoming bought a new stake in Harrow in the first quarter worth about $97,000. Institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.